Dana Tedesco1, Manoj Thapa1, Chui Yoke Chin2, Yong Ge3, Minghao Gong3, Jing Li3, Sanjeev Gumber4, Patrick Speck1, Elizabeth J Elrod1, Eileen M Burd5, William H Kitchens6, Joseph F Magliocca6, Andrew B Adams6, David S Weiss7, Mansour Mohamadzadeh8, Arash Grakoui9. 1. Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia. 2. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia. 3. Department of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida. 4. Division of Pathology and Laboratory Medicine, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia. 5. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia. 6. Department of Surgery, Transplant, Emory University School of Medicine, Atlanta, Georgia. 7. Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; Emory Antibiotic Resistance Center, Atlanta, Georgia. 8. Department of Infectious Disease and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida; Division of Hepatology, Gastroenterology, and Nutrition; University of Florida, Gainesville, Florida. 9. Emory Vaccine Center, Division of Microbiology and Immunology, Yerkes Research Primate Center, Emory University School of Medicine, Atlanta, Georgia; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Electronic address: arash.grakoui@emory.edu.
Abstract
BACKGROUND & AIMS: Variants at the ABCB4 or MDR2 locus, which encodes a biliary transport protein, are associated with a spectrum of cholestatic liver diseases. Exacerbation of liver disease has been linked to increased hepatic levels of interleukin (IL) 17, yet the mechanisms of this increase are not understood. We studied mice with disruption of Mdr2 to determine how defects in liver and alteration in the microbiota contribute to production of IL17 by intrahepatic γδ T cells. METHODS: We performed studies with Mdr2-/- and littermate FVB/NJ (control) mice. IL17 was measured in serum samples by an enzyme-linked immunosorbent assay. Mice were injected with neutralizing antibodies against the γδ T-cell receptor (TCR; anti-γδ TCR) or mouse IL17A (anti-IL17A). Livers were collected and bacteria were identified in homogenates by culture procedures; TCRγδ+ cells were isolated by flow cytometry. Fecal samples were collected from mice and analyzed by 16S ribosomal DNA sequencing. Cells were stimulated with antibodies or bacteria, and cytokine production was measured. We obtained tissues from 10 patients undergoing liver transplantation for primary sclerosing cholangitis or chronic hepatitis C virus infection. Tissues were analyzed for cytokine production by γδ TCR+ cells. RESULTS: Mdr2-/- mice had collagen deposition around hepatic bile ducts and periportal-bridging fibrosis with influx of inflammatory cells and increased serum levels of IL17 compared with control mice. Administration of anti-IL17A reduced hepatic fibrosis. Livers from Mdr2-/- mice had increased numbers of IL17A+ γδTCR+ cells-particularly of IL17A+ Vγ6Jγ1 γδ TCR+ cells. Fecal samples from Mdr2-/- mice were enriched in Lactobacillus, and liver tissues were enriched in Lactobacillus gasseri compared with control mice. Mdr2-/- mice also had increased intestinal permeability. The γδ TCR+ cells isolated from Mdr2-/- livers produced IL17 in response to heat-killed L gasseri. Intraperitoneal injection of control mice with L gasseri led to increased serum levels of IL17 and liver infiltration by inflammatory cells; injection of these mice with anti-γδ TCR reduced serum level of IL17. Intravenous injections of Mdr2-/- mice with anti-γδ TCR reduced fibrosis; liver levels of IL17, and inflammatory cells; and serum levels of IL17. γδTCR+ cells isolated from livers of patients with primary sclerosing cholangitis, but not hepatitis C virus infection, produced IL17. CONCLUSIONS: In Mdr2-/- mice, we found development of liver fibrosis and inflammation to require hepatic activation of γδ TCR+ cells and production of IL17 mediated by exposure to L gasseri. This pathway appears to contribute to development of cholestatic liver disease in patients.
BACKGROUND & AIMS: Variants at the ABCB4 or MDR2 locus, which encodes a biliary transport protein, are associated with a spectrum of cholestatic liver diseases. Exacerbation of liver disease has been linked to increased hepatic levels of interleukin (IL) 17, yet the mechanisms of this increase are not understood. We studied mice with disruption of Mdr2 to determine how defects in liver and alteration in the microbiota contribute to production of IL17 by intrahepatic γδ T cells. METHODS: We performed studies with Mdr2-/- and littermate FVB/NJ (control) mice. IL17 was measured in serum samples by an enzyme-linked immunosorbent assay. Mice were injected with neutralizing antibodies against the γδ T-cell receptor (TCR; anti-γδ TCR) or mouseIL17A (anti-IL17A). Livers were collected and bacteria were identified in homogenates by culture procedures; TCRγδ+ cells were isolated by flow cytometry. Fecal samples were collected from mice and analyzed by 16S ribosomal DNA sequencing. Cells were stimulated with antibodies or bacteria, and cytokine production was measured. We obtained tissues from 10 patients undergoing liver transplantation for primary sclerosing cholangitis or chronic hepatitis C virus infection. Tissues were analyzed for cytokine production by γδ TCR+ cells. RESULTS:Mdr2-/- mice had collagen deposition around hepatic bile ducts and periportal-bridging fibrosis with influx of inflammatory cells and increased serum levels of IL17 compared with control mice. Administration of anti-IL17A reduced hepatic fibrosis. Livers from Mdr2-/- mice had increased numbers of IL17A+ γδTCR+ cells-particularly of IL17A+ Vγ6Jγ1 γδ TCR+ cells. Fecal samples from Mdr2-/- mice were enriched in Lactobacillus, and liver tissues were enriched in Lactobacillus gasseri compared with control mice. Mdr2-/- mice also had increased intestinal permeability. The γδ TCR+ cells isolated from Mdr2-/- livers produced IL17 in response to heat-killed L gasseri. Intraperitoneal injection of control mice with L gasseri led to increased serum levels of IL17 and liver infiltration by inflammatory cells; injection of these mice with anti-γδ TCR reduced serum level of IL17. Intravenous injections of Mdr2-/- mice with anti-γδ TCR reduced fibrosis; liver levels of IL17, and inflammatory cells; and serum levels of IL17. γδTCR+ cells isolated from livers of patients with primary sclerosing cholangitis, but not hepatitis C virus infection, produced IL17. CONCLUSIONS: In Mdr2-/- mice, we found development of liver fibrosis and inflammation to require hepatic activation of γδ TCR+ cells and production of IL17 mediated by exposure to L gasseri. This pathway appears to contribute to development of cholestatic liver disease in patients.
Authors: J J Smit; A H Schinkel; R P Oude Elferink; A K Groen; E Wagenaar; L van Deemter; C A Mol; R Ottenhoff; N M van der Lugt; M A van Roon Journal: Cell Date: 1993-11-05 Impact factor: 41.582
Authors: Peter Fickert; Andrea Fuchsbichler; Martin Wagner; Gernot Zollner; Arthur Kaser; Herbert Tilg; Robert Krause; Frank Lammert; Cord Langner; Kurt Zatloukal; Hanns-Ulrich Marschall; Helmut Denk; Michael Trauner Journal: Gastroenterology Date: 2004-07 Impact factor: 22.682
Authors: Christian Klemann; Arne Schröder; Anika Dreier; Nora Möhn; Stephanie Dippel; Thomas Winterberg; Anne Wilde; Yi Yu; Anja Thorenz; Faikah Gueler; Anne Jörns; Eva Tolosa; Johannes Leonhardt; Jan D Haas; Immo Prinz; Gertrud Vieten; Claus Petersen; Joachim F Kuebler Journal: Gastroenterology Date: 2015-09-25 Impact factor: 22.682
Authors: Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui Journal: J Immunol Date: 2020-04-24 Impact factor: 5.422
Authors: Qianfei Zhang; Chi Ma; Yi Duan; Bernd Heinrich; Umberto Rosato; Laurence P Diggs; Lichun Ma; Soumen Roy; Qiong Fu; Zachary J Brown; Simon Wabitsch; Vishal Thovarai; Jianyang Fu; Dechun Feng; Benjamin Ruf; Linda L Cui; Varun Subramanyam; Karen M Frank; Sophie Wang; David E Kleiner; Thomas Ritz; Christian Rupp; Bin Gao; Thomas Longerich; Alexander Kroemer; Xin Wei Wang; Mathuros Ruchirawat; Firouzeh Korangy; Bernd Schnabl; Giorgio Trinchieri; Tim F Greten Journal: Cancer Discov Date: 2020-12-15 Impact factor: 38.272